Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

(TheNewswire)

Toronto, Ontario – TheNewswire - January 7, 2026 -- Ventripoint Diagnostics Ltd. (Ventripoint or the Corporation,TSXV:VPT), a leading innovator in AI-powered cardiac imagingtechnology, today announced, in response to significant investorinterest, it will double its previously announced non-brokered privateplacement (“Offering”) (See press release December 30,2025) from $500,000 to $1,000,000 subject to TSX Venture Exchange(“TSXV or theExchange”) approval.

Each Unit will be comprised of one (1) common share(“Common Shares”) of the Corporation, and one (1) common share purchasewarrant (“Warrants”).

Each whole Warrant will entitlethe holder thereof to purchase one (1) Common Share at a price of$0.13 for a period of 24 months from the closing of the Offering. TheCorporation reserves the right to accelerate the Warrant expiry periodupon 30 days notice, if the Common Shares trade at $0.26 or above onthe TSXV for a period of 10 consecutive days, including days where notrades occur.

The Corporation may pay cash finder’s fee and issuecommon share purchase warrants (“Finder’s Warrants”) of up to 8% of the gross proceeds of the Offering. EachFinder’s Warrant will be exercisable into one Common Share at anexercise price of CDN$0.13 per Common Share for a period of 24months from the closing of the Offering.

The Corporation will use the proceeds of the Offeringto support critical commercializationactivities, manufacturing scale-up, continued regulatory submissions,and operational requirements.

All securities issued and issuable pursuant to theOffering will be subject to a hold period of four months plus one dayfrom the date of closing of the Offering. The Offering is subject toapproval by the Exchange.

The securities offered will not beregistered under the U.S. Securities Act of 1933, as amended, and maynot be offered or sold in the United States absent a registrationstatement or an applicable exemption from the registrationrequirements. The press release shall not constitute an offer to sellor the solicitation of an offer to buy nor shall there be any sale ofthe securities in any State in which such offer, solicitation or salewould be unlawful.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS+ products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in theCorporation's most recent annual management's discussion andanalysis that is available on the Corporation's profile on SEDAR+at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors isnot exhaustive. The forward-looking statements included in this newsrelease are expressly qualified by this cautionary statement. Theforward-looking statements and information contained in this newsrelease are made as of the date hereof and the Corporation undertakesno obligation to update publicly or revise any forward-lookingstatements or information, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.

NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITEDSTATES

Copyright (c) 2026 TheNewswire - All rights reserved.